- In a $480 million deal, Zenas, a Shanghai-Boston biopharma, acquired global rights to a bifunctional antibody from Xencor that targets CD19.
- Beijing's BeiGene closed on a 42-acre US site in the Princeton, NJ area where it will build a manufacturing center and house clinical R&D operations.
- 3D Medicines reported that China's NMPA approved the launch of its anti-PD-L1 therapy, the first subcutaneously administered anti-PD-L1 approved anywhere in the world.
For further details see:
Week In Review: Shanghai's Zenas Acquires CD19 Antibody From Xencor In $480 Million Deal